## Jose Flores

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/487709/publications.pdf

Version: 2024-02-01

477173 567144 47 911 15 29 citations h-index g-index papers 49 49 49 1347 all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	Variantes del gen ABCB1 como factores de riesgo y factores moduladores de la edad de inicio en pacientes mexicanos con enfermedad desmielinizante. NeurologÃa, 2023, 38, 65-74.	0.3	2
2	Cyclophosphamide treatment in active multiple sclerosis. Neurological Sciences, 2021, 42, 3775-3780.	0.9	14
3	An Abnormally High Neutrophil-to-Lymphocyte Ratio Is Not an Independent Outcome Predictor in AQP4-IgG-Positive NMOSD. Frontiers in Immunology, 2021, 12, 628024.	2.2	21
4	Perceived discrimination in patients with multiple sclerosis and depressive symptomatology. Multiple Sclerosis and Related Disorders, 2021, 48, 102705.	0.9	3
5	Onychomycosis in patients with multiple sclerosis: prevalence, clinical description, mycological, and dermoscopic study in a Mexican population. International Journal of Dermatology, 2021, 60, 1102-1108.	0.5	O
6	A Metabolic Brain Pattern Associated With Anti-N-Methyl-D-Aspartate Receptor Encephalitis. Psychosomatics, 2020, 61, 39-48.	2.5	26
7	Herpes viruses in optic neuritis: Similar to Bell's palsy. Clinical Neurology and Neurosurgery, 2020, 188, 105588.	0.6	4
8	Antiâ€aquaporinâ€4 antibodyâ€positive neuromyelitis optica spectrum disorder associated with central nervous system tuberculosis. Clinical and Experimental Neuroimmunology, 2020, 11, 40-44.	0.5	0
9	Acute optic nerve lesions in first-ever NMOSD-related optic neuritis using conventional brain MRI: A Latin American multicenter study. Multiple Sclerosis and Related Disorders, 2020, 46, 102558.	0.9	5
10	Continuous Visual Focal Status Epilepticus as the Primary Presentation of NMDA-R and GAD65-R Autoimmune Epilepsy. Frontiers in Neurology, 2020, $11$ , $598974$ .	1.1	1
11	Latin American consensus recommendations for management and treatment of neuromyelitis optica spectrum disorders in clinical practice. Multiple Sclerosis and Related Disorders, 2020, 45, 102428.	0.9	42
12	Native American ancestry significantly contributes to neuromyelitis optica susceptibility in the admixed Mexican population. Scientific Reports, 2020, 10, 13706.	1.6	18
13	Rituximab efficacy at different initial and maintenance doses in neuromyelitis optica spectrum disorder: Experience from a national health institute in México. Journal of the Neurological Sciences, 2020, 419, 117204.	0.3	9
14	AQP4-lgG-positive neuromyelitis optica spectrum disorder with late onset in Mexico Multiple Sclerosis and Related Disorders, 2020, 43, 102221.	0.9	5
15	Effect of rituximab on disease activity in latin American patients with anti-aquaporin-4 (+) neuromyelitis optica spectrum disorder. Clinical Neurology and Neurosurgery, 2020, 196, 106007.	0.6	3
16	Rituximab as an effective therapeutic option in refractory Neuro-Behçet syndrome. Journal of Neuroimmunology, 2020, 346, 577308.	1,1	7
17	Diversity of HLA Class I and Class II blocks and conserved extended haplotypes in Lacandon Mayans. Scientific Reports, 2020, 10, 3248.	1.6	11
18	Palatal tremor and intact Guillainâ€Mollaret triangle secondary to Hashimoto's encephalopathy. Clinical and Experimental Neuroimmunology, 2020, 11, 192-195.	0.5	0

#	Article	IF	CITATIONS
19	Severe fingolimod rebound syndrome after switching to cladribine treatment. Multiple Sclerosis and Related Disorders, 2020, 40, 101938.	0.9	9
20	"Reply: Methodological and Ethical Concerns in the Study of AntiNMDA Encephalitis With Positron Emission Tomography― Psychosomatics, 2020, 61, 863-864.	2.5	0
21	The monetary burden of cysticercosis in Mexico. PLoS Neglected Tropical Diseases, 2019, 13, e0007501.	1.3	19
22	Air Pollution, Multiple Sclerosis and its Relevance to Mexico City. Archives of Medical Research, 2019, 50, 111-112.	1.5	11
23	Catatonia in patients with antiâ€NMDA receptor encephalitis. Psychiatry and Clinical Neurosciences, 2019, 73, 574-580.	1.0	54
24	$\hat{l}_{\pm}$ -Ga <sub>2</sub> O <sub>3</sub> as a Photocatalyst in the Degradation of Malachite Green. ECS Journal of Solid State Science and Technology, 2019, 8, Q3180-Q3186.	0.9	33
25	Sildenafil Inhibits Myelin Expression and Myelination of Oligodendroglial Precursor Cells. ASN Neuro, 2019, 11, 175909141983244.	1.5	10
26	Dopaminergic Hyperactivity in Neurological Patients with Delirium. Archives of Medical Research, 2019, 50, 477-483.	1.5	10
27	Remyelination in multiple sclerosis: from concept to clinical trials. Current Opinion in Neurology, 2019, 32, 378-384.	1.8	28
28	Neurocysticercosis: mimics and chameleons. Practical Neurology, 2019, 19, 88-95.	0.5	9
29	Frequency of neuropsychiatric disturbances in antiâ€NMDA receptor encephalitis. Acta Psychiatrica Scandinavica, 2018, 138, 483-485.	2.2	12
30	Varicella-Zoster Virus in Cerebrospinal Fluid at Relapses of Multiple Sclerosis is Infective inÂVitro. Archives of Medical Research, 2018, 49, 350-355.	1.5	4
31	Pre-hospitalization, hospitalization, and post-hospitalization costs of patients with neurocysticercosis treated at the Instituto Nacional de Neurologia y Neurocirugia (INNN) in Mexico City, Mexico. Revista Do Instituto De Medicina Tropical De Sao Paulo, 2018, 60, e20.	0.5	3
32	Obstetric outcomes in a Mexican cohort of patients with AQP4-antibody-seropositive neuromyelitis optica. Multiple Sclerosis and Related Disorders, 2018, 25, 268-270.	0.9	13
33	Opisthotonus (arc de cercle) in anti-NMDAR encephalitis. Arquivos De Neuro-Psiquiatria, 2018, 76, 426-426.	0.3	2
34	Papel de las enfermedades infecciosas en el desarrollo de la esclerosis múltiple: evidencia cientÃfica. Neurologia Argentina, 2017, 9, 40-48.	0.1	0
35	Vitamin D receptor gene polymorphisms are associated with multiple sclerosis in Mexican adults. Journal of Neuroimmunology, 2017, 306, 20-24.	1.1	23
36	Cigarette Smoking, Alcohol Consumption and Overweight in Multiple Sclerosis: Disability Progression. Archives of Medical Research, 2017, 48, 113-120.	1.5	26

#	Article	IF	CITATIONS
37	The genetics of multiple sclerosis in Latin America. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2017, 3, 205521731772729.	0.5	4
38	Cost of neurocysticercosis patients treated in two referral hospitals in <scp>M</scp> exico <scp>C</scp> ity, <scp>M</scp> exico. Tropical Medicine and International Health, 2015, 20, 1108-1119.	1.0	11
39	Sunlight exposure and multiple sclerosis in a tropical country. Neurological Research, 2014, 36, 647-650.	0.6	14
40	Cognitive and neuropsychiatric disorders among multiple sclerosis patients from Latin America: Results of the RELACCEM study. Multiple Sclerosis and Related Disorders, 2014, 3, 335-340.	0.9	16
41	The participation of varicella zoster virus in relapses of multiple sclerosis. Clinical Neurology and Neurosurgery, 2014, 119, 44-48.	0.6	43
42	The investigation of acute optic neuritis: a review and proposed protocol. Nature Reviews Neurology, 2014, 10, 447-458.	4.9	248
43	Vitamina D y Esclerosis Múltiple: Evidencia cientÃfica. Neurologia Argentina, 2013, 5, 250-258.	0.1	1
44	Estimating the Non-Monetary Burden of Neurocysticercosis in Mexico. PLoS Neglected Tropical Diseases, 2012, 6, e1521.	1.3	61
45	Multiple sclerosis in Caucasians and Latino Americans. Autoimmunity, 2011, 44, 571-575.	1.2	20
46	Quality of Life in Patients with Neurocysticercosis in Mexico. American Journal of Tropical Medicine and Hygiene, 2011, 84, 782-786.	0.6	28
47	Varicella zoster virus in progressive forms of multiple sclerosis. Clinical Neurology and Neurosurgery, 2010, 112, 653-657.	0.6	23